Triple-action cancer jab wipes out head-and-neck tumours in international trial

An international trial of 102 patients with HPV-negative head and neck cancer found that amivantamab, a subcutaneously injected jab, shrank tumours in 43 patients and completely eradicated them in 15, including in cancers resistant to chemotherapy and immunotherapy. The triple-action antibody blocks EGFR and MET and stimulates the immune system, and showed manageable side effects with most patients able to continue treatment; median overall survival was 12.5 months. The drug is also being explored in other cancers and results were to be presented at ASCO.